KLDO News and Press, Kaleido Biosciences Inc. From 10/30/19

Kaleido Biosciences (NASDAQ: KLDO ): Q3 GAAP EPS of -$0.74 beats by $0.13 . More news on: Kaleido BioSciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- Executing Pipeline Towards Key Clinical Data Readouts in Q4 2019 and 2020 - Focusing Resources on Pipeline Programs and Extending Cash Runway   LEXINGTON, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare compa...

LEXINGTON, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, has entered into a research collaboration with Jef...

For an equity market that has hit all-time highs on multiple occasions during this year, one would think that investors would be salivating over IPOs for a chance to "get in from the beginning" and bidding them higher in the process. The reality, though, is that IPOs have been one of the more ...

Additional Presentation on Platform at Upcoming Keystone Symposia on the Microbiome: Therapeutic Implications LEXINGTON, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging ...

LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Jean Mixer has been appo...

LEXINGTON, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Joshua Brumm will step d...

Cancer patients who receive an antibiotic within one month of receiving a checkpoint inhibitor achieve a median survival of just two months. Those who don't take an antibiotic and receive the same treatment achieve a median survival of 26 months, fully 1,200% longer. The significant gap is thoug...

LEXINGTON, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced plans to develop Microbiome Met...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...